Notice
Progress of NovDB2, NovOB Phase 2c clinical trial
Registration date : 2020.11.20
Here are new updates from NovMetaPharma.
US FDA is conducting Phase 2c clinical trial of our insulin sensitivity treatment drug (NovDB2) and our obesity treatment drug (NovOB) as follows.
* This data was originally scheduled to be submitted at the end of August to obtain FDA approval at the end of September, but it was submitted on the above date, which is 20 days behind schedule, to verify data accuracy.
Attach Files : none
- < Prev There is no previous post.
- Next > Submission of manuscript to scientific journal